🇺🇸 FDA
Patent

US 11352639

Gene therapy based on vector VTVAF17

granted A61KA61K48/00A61K48/005

Quick answer

US patent 11352639 (Gene therapy based on vector VTVAF17) held by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “ALLEL TSENTR INNOVATSIONNYKH BIOTEKHNOLOGY” expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “ALLEL TSENTR INNOVATSIONNYKH BIOTEKHNOLOGY”
Grant date
Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K48/00, A61K48/005